

Mohamed Abou El-Enein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8571550/publications.pdf>

Version: 2024-02-01

35
papers

1,315
citations

361413

20
h-index

395702

33
g-index

37
all docs

37
docs citations

37
times ranked

1443
citing authors

#	ARTICLE	IF	CITATIONS
1	The Value of CAR-T-cell Immunotherapy in Cancer. , 2022, , 231-234.		2
2	Adoptive transfer of exÂvivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD. Molecular Therapy, 2022, 30, 2298-2314.	8.2	16
3	Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nature Reviews Clinical Oncology, 2022, 19, 342-355.	27.6	113
4	Immunogenicity of CAR T cells in cancer therapy. Nature Reviews Clinical Oncology, 2021, 18, 379-393.	27.6	128
5	Detection of SARSâ€CoVâ€2â€specific memory B cells to delineate longâ€term COVIDâ€19 immunity. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2595-2599.	5.7	7
6	Unproven stem cell interventions: A global public health problem requiring global deliberation. Stem Cell Reports, 2021, 16, 1435-1445.	4.8	23
7	Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy. Blood Cancer Discovery, 2021, 2, 408-422.	5.0	84
8	Evidence generation and reproducibility in cell and gene therapy research: A call to action. Molecular Therapy - Methods and Clinical Development, 2021, 22, 11-14.	4.1	13
9	Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies. Molecular Therapy, 2020, 28, 2108-2110.	8.2	4
10	COVID-19-Induced ARDS Is Associated with Decreased Frequency of Activated Memory/Effector T Cells Expressing CD11a+. Molecular Therapy, 2020, 28, 2691-2702.	8.2	35
11	Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial. BMJ, The, 2020, 371, m3734.	6.0	101
12	Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals. Molecular Therapy - Methods and Clinical Development, 2020, 18, 269-279.	4.1	29
13	Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy. Trends in Biotechnology, 2020, 38, 1099-1112.	9.3	68
14	CAR T-cell product performance in haematological malignancies before and after marketing authorisation. Lancet Oncology, The, 2020, 21, e104-e116.	10.7	57
15	The Human Genome Editing Race: Loosening Regulatory Standards for Commercial Advantage?. Trends in Biotechnology, 2019, 37, 120-123.	9.3	20
16	Cell and Gene Therapy Trials: Are We Facing an â€Evidence Crisisâ€™?. EClinicalMedicine, 2019, 7, 13-14.	7.1	26
17	Linking Scattered Stem Cell-Based Data to Advance Therapeutic Development. Trends in Molecular Medicine, 2019, 25, 8-19.	6.7	6
18	Post-marketing safety and efficacy surveillance of cell and gene therapies in the EU: A critical review. Cell & Gene Therapy Insights, 2019, 5, 1505-1521.	0.1	12

#	ARTICLE	IF	CITATIONS
19	Registry Contributions to Strengthen Cell and Gene Therapeutic Evidence. <i>Molecular Therapy</i> , 2018, 26, 1172-1176.	8.2	25
20	Enhancing patient-level clinical data access to promote evidence-based practice and incentivize therapeutic innovation. <i>Advanced Drug Delivery Reviews</i> , 2018, 136-137, 97-104.	13.7	14
21	Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions. <i>Stem Cells Translational Medicine</i> , 2018, 7, 676-685.	3.3	114
22	Telbivudine in chronic lymphocytic myocarditis and human parvovirus <scp>B19</scp> transcriptional activity. <i>ESC Heart Failure</i> , 2018, 5, 818-829.	3.1	36
23	The path to successful commercialization of cell and gene therapies: empowering patient advocates. <i>Cytotherapy</i> , 2017, 19, 293-298.	0.7	18
24	Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment. <i>Cell Stem Cell</i> , 2017, 21, 427-430.	11.1	24
25	Accelerating Patients' Access to Advanced Therapies in the EU. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 7, 15-19.	4.1	19
26	Clinical Development of Cell Therapies: Setting the Stage for Academic Success. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 35-38.	4.7	14
27	Strategies for Derisking Translational Processes for Biomedical Technologies. <i>Trends in Biotechnology</i> , 2017, 35, 100-108.	9.3	26
28	Overcoming Challenges Facing Advanced Therapies in the EU Market. <i>Cell Stem Cell</i> , 2016, 19, 293-297.	11.1	114
29	Putting a price tag on novel autologous cellular therapies. <i>Cytotherapy</i> , 2016, 18, 1056-1061.	0.7	32
30	Deciphering the EU clinical trials regulation. <i>Nature Biotechnology</i> , 2016, 34, 231-233.	17.5	19
31	Clinical translation of viral vectors for gene therapies and beyond. <i>Cell & Gene Therapy Insights</i> , 2016, 2, 507-511.	0.1	0
32	Gene therapy: a possible future standard for HIV care. <i>Trends in Biotechnology</i> , 2015, 33, 374-376.	9.3	8
33	The business case for cell and gene therapies. <i>Nature Biotechnology</i> , 2014, 32, 1192-1193.	17.5	28
34	A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV. <i>Trends in Molecular Medicine</i> , 2014, 20, 632-642.	6.7	23
35	Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs. <i>Cytotherapy</i> , 2013, 15, 362-383.	0.7	57